Why is CVS conducting these tender offers?

According to the press release, the purpose is to retire a portion of CVS Health's outstanding indebtedness. The company expects to fund the offers with net proceeds from a new issuance of subordinated debt securities, which suggests active liability management and a refinancing of existing senior notes.

What happens if CVS cannot raise enough money from the new notes?

The tender offers are subject to CVS issuing New Notes in an amount sufficient to fund the purchases, along with accrued interest and fees, on terms reasonably satisfactory to CVS. If the proceeds are insufficient, CVS may choose not to consummate any of the offers or to fund them with cash.

How much will holders receive, and what is the early tender incentive?

Holders receive a total consideration per $1,000 of principal, set by a fixed spread over a U.S. Treasury yield. Maximum Tender Offer Notes tendered by December 13, 2024 receive an additional $30 per $1,000 early tender payment. Tenders after that date receive only the tender offer consideration, which excludes the early payment, through the December 31, 2024 expiration.

Which notes are most likely to be accepted, and does the order matter?

Acceptance is governed by priority levels 1 through 10, applied up to the $2.0 billion maximum aggregate purchase price. Lower-numbered series, such as the 2.700% 2040 notes at level 1, have higher priority. Larger or lower-priority series, such as the $8.0 billion 5.050% 2048 notes at level 8, may be prorated or not accepted in full, depending on total tender volume.

What is the near-term impact on CVS's debt profile?

If the 2025 notes are fully tendered, CVS would retire roughly $950 million of debt maturing in March 2025, which reduces near-term maturity obligations. The longer-dated notes that are tendered would be replaced by subordinated debt, which typically ranks below senior debt and may carry a higher cost. The exact effect depends on final participation and the terms of the new issuance, which were not disclosed in this filing.

CVS 8-K SEC Disclosure

01—Abstract

Summary

Summary of the 8-K filed December 2, 2024. Cited figures are marked; the original filing is the authoritative source.

On December 2, 2024, CVS Health commenced cash tender offers for its own and Aetna's senior notes.

The offers cover (1) any and all of the 4.100% Senior Notes due 2025, about $950 million^a outstanding and maturing March 25, 2025, and (2) up to a $2.0 billion aggregate purchase price of nine other series, with acceptance priority levels set in numerical order. The stated purpose is to retire a portion of CVS's outstanding debt. The company expects to fund the offers with net proceeds from a planned issuance of subordinated debt securities.

The timeline has two key dates. Any and All Notes must be tendered by December 6, 2024, with settlement expected December 11. Maximum Tender Offer Notes tendered by the December 13 early tender date receive an early tender payment of $30^b per $1,000 principal, and settlement may occur as early as December 18.

The final expiration for those notes is December 31, 2024. Pricing is set as a U.S. Treasury yield plus a fixed spread, which ranges from +25 bps on the 2025 notes to +156 bps on the 5.050%^c 2048 notes. For investors, the main points are a near-term reduction in debt maturities and a shift in the capital structure toward subordinated debt.

The offers are not conditioned on a minimum tender amount, but they depend on CVS issuing enough new notes to fund them. If that funding is not raised, CVS may cancel the offers or fund them with cash. The filing is a tender-offer announcement, not an earnings release, and it contains no updated operating or financial results.

02—Key points

Key Highlights

CVS launched cash tender offers for its 4.100% Senior Notes due 2025 (about $950.1 million outstanding, maturing March 25, 2025), with a total of up to $2.0 billion of purchase price across the Any and All and Maximum Tender Offers.
The Maximum Tender Offer covers nine series of CVS and Aetna notes maturing between 2030 and 2050, including the $8.0 billion 5.050% Senior Notes due 2048, which is ranked lower in acceptance priority and may be prorated.
Key deadlines: Any and All Notes tender and withdrawal deadline of December 6, 2024 (settlement expected December 11); Maximum Tender Offer early tender date of December 13, 2024 (early settlement possible as early as December 18); final expiration on December 31, 2024.
Holders who tender by the early tender date receive a $30 per $1,000 principal early tender payment, included in the total consideration.
Pricing is a fixed spread over a U.S. Treasury reference yield, ranging from +25 bps (2025 notes) to +156 bps (5.050% 2048 notes), set at 11:00 a.m. ET on December 6 for Any and All Notes and 10:00 a.m. ET on December 16 for Maximum Tender Offer Notes.
The offers are funded by planned issuance of subordinated debt, and CVS may not consummate them if sufficient proceeds are not raised, creating a financing contingency.
Barclays and Mizuho are dealer managers, and D.F. King & Co. is the tender and information agent. The filing also incorporates Exhibit 99.1 and the Offer to Purchase dated December 2, 2024.

03—Questions

Frequently Asked Questions

Why is CVS conducting these tender offers?
According to the press release, the purpose is to retire a portion of CVS Health's outstanding indebtedness. The company expects to fund the offers with net proceeds from a new issuance of subordinated debt securities, which suggests active liability management and a refinancing of existing senior notes.
What happens if CVS cannot raise enough money from the new notes?
The tender offers are subject to CVS issuing New Notes in an amount sufficient to fund the purchases, along with accrued interest and fees, on terms reasonably satisfactory to CVS. If the proceeds are insufficient, CVS may choose not to consummate any of the offers or to fund them with cash.
How much will holders receive, and what is the early tender incentive?
Holders receive a total consideration per $1,000 of principal, set by a fixed spread over a U.S. Treasury yield. Maximum Tender Offer Notes tendered by December 13, 2024 receive an additional $30 per $1,000 early tender payment. Tenders after that date receive only the tender offer consideration, which excludes the early payment, through the December 31, 2024 expiration.
Which notes are most likely to be accepted, and does the order matter?
Acceptance is governed by priority levels 1 through 10, applied up to the $2.0 billion maximum aggregate purchase price. Lower-numbered series, such as the 2.700% 2040 notes at level 1, have higher priority. Larger or lower-priority series, such as the $8.0 billion 5.050% 2048 notes at level 8, may be prorated or not accepted in full, depending on total tender volume.
What is the near-term impact on CVS's debt profile?
If the 2025 notes are fully tendered, CVS would retire roughly $950 million of debt maturing in March 2025, which reduces near-term maturity obligations. The longer-dated notes that are tendered would be replaced by subordinated debt, which typically ranks below senior debt and may carry a higher cost. The exact effect depends on final participation and the terms of the new issuance, which were not disclosed in this filing.

04—Continue

← View all 8-K filings